11.17 USD
▼-0.04-0.36%
盘后 11.19 +0.18%
2026-09-15
市值
$212.94M
市盈率
—
EPS
-3.10
股息率
—
52 周区间
9.69 – 22.55
成交量
199.98K
Beta
1.02
目标价
19.83
52W 低 9.6952W 高 22.55
价格走势
公司简介
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that...